CARY, N.C., May. 21 /PRNewswire/ -- inGenium Research, Inc. (inGenium) has entered into an agreement with Peregrine Pharmaceuticals, Inc. of Tustin, Calif., to assist in the development and partnering of a novel monoclonal antibody that may be used to treat cancer.
The terms of the agreement involve clinical, scientific, business development and regulatory assistance to Peregrine during the pre-clinical evaluation of this novel cancer therapeutic.
"This agreement typifies the services that inGenium is capable of providing to its clients," said Joshua S. Baker, president and CEO of inGenium. "Our new partners at Peregrine have an extensive development portfolio of cancer therapeutics, including therapeutic monoclonal antibodies, anti-angiogenesis therapies, and chemotherapy-enhancing treatments. We are very excited to be working with such a solid and well-respected biotechnology company."
inGenium Research is a privately held Contract Research Organization (CRO) located in Cary, North Carolina, focused on providing clinical research and strategic development services to pharmaceutical and biotechnology companies. inGenium provides assistance to companies in the areas of strategic planning, technology transfer, licensing, regulatory planning and submissions, pre-clinical development, and manufacturing, as well as providing fully integrated clinical trials support of clinical operations, data management and biostatistics, and regulatory dossier compilations.
For information contact:
Josh Baker, President and CEO Dan Headrick
inGenium Research, Inc. Public Relations
inGenium Research, Inc.
CONTACT: Josh Baker, President and CEO of inGenium Research, Inc.,+1-919-462-8867, or email@example.com; or Dan Headrick, Public Relationsfor inGenium Research, Inc., +1-919-332-9303, or firstname.lastname@example.org